[Efficacy of various treatments in the management of XXXX in the adult].

@entity1 @entity1667 @entity229 @entity1872 @entity134 @entity281 @entity1891 @entity3039 @entity1499 @entity5713
PURPOSE: To evaluate the @entity3039 treatment modalities and their results in a series of 30 adult @entity1 . @entity1 AND METHODS: 30 @entity1 , age 15-74, were diagnosed of @entity3039 in our institution between 1988 and December 1991. We defined the @entity3039 as: mild (platelets > or = 50 x 10(9)/L and < or = 120 x 10(9)/L), moderate (platelets 25-50 x 10(9)/L) and severe (platelets < or = 25 x 10(9)/L). Treatment was initiated when the platelet count reached a level < 50 x 10(9)/L. Initial therapy was oral @entity229 or @entity1667 in all @entity1 . In 12 unresponsive @entity1 the treatment included splenectomy. @entity1 who fail @entity134 therapy and splenectomy received additional lines of therapy, that included: @entity1891 (n = 2), @entity5713 (n = 1), @entity1872 (n = 5), anti D immunoglobulin (n = 6), @entity1499 (n = 2), intravenous immunoglobulin (n = 3). RESULTS: Complete remission was obtained in 19 @entity1 with a follow-up of 3 to 55 months (median, 30 months). Partial remission was achieved in 4 @entity1 , that was sustained for 9 to 39 months (median, 22.5 months) after initial therapy. One unresponsive @entity1 died of @entity281 . Six mild @entity3039 @entity1 did not require therapy with a follow-up of 14 to 56 months (median, 33.1 months). CONCLUSION: In adult @entity1 with mild @entity3039 , therapy is not required. @entity134 therapy remains the initial therapeutic choice for moderate and severe @entity3039 . In unresponsive @entity1 useful alternative choices are splenectomy, danazol, anti D immunoglobulin and @entity1499 .
